It is our intention to pursue prospective targets that are focused on healthcare innovation. (Incorporated in the Cayman Islands)

We anticipate targeting what are traditionally known as “small cap” companies domiciled in North America, Europe and/or the Asia Pacific (“APAC”) regions that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics space which aligns with our management team’s experience in operating health care companies and in drug and device technology development as well as diagnostic and other services. We shall not undertake our initial business combination with a target business with its principal business operations in China (including Hong Kong and Macau).

(Note: Aimei Healthcare Technology Co. Ltd. priced its SPAC IPO in sync with the terms in its prospectus – 6.0 million units at $10.00 – to raise $60.0 million after the U.S. stock market’s close on Friday, Dec. 1, 2023. The stock is expected to start trading Monday, Dec. 4, 2023, on the NASDAQ.) 

(Note: Aimei Healthcare Technology Co. Ltd. increased its SPAC IPO’s size to 6.0 million units – up from 5.0 million units – at $10.00 to raise $60.0 million, according to an S-1/A filing dated Oct. 27, 2023.)

(Note: Aimei Healthcare Technology Co. Ltd. filed an S-1/A dated Oct. 6, 2023, in which it dropped the warrants from its SPAC IPO. The unit now consists of one share of stock and one right to receive one-fifth (1/5) of one ordinary share upon the consummation of an initial business combination.)

(Background: Aimei Healthcare Technology Co. Ltd. filed its S-1 on May 26, 2023, with its IPO terms: 5.0 million units at $10.00 each to raise $50.0 million. Each unit consists of one ordinary share, one right and one warrant, which we refer to throughout this prospectus as the “public warrants.” Each right entitles the holder thereof to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination, as described in more detail in this prospectus. Each warrant entitles the holder thereof to purchase three-fourths (3/4) of one ordinary share at a price of $11.50 per whole share, subject to adjustment as described in the prospectus.)